Verification evidence is still being completed.
PDF / print export
Mabion S.A.
Łódź, Poland
- Verified lead
- Gregor Kawaletz
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer and President of the Management Board
- 2026 technical specialization
- CMO for Recombinant Proteins
- Review cycle
- May 2026
- Full address
- gen. Mariana Langiewicza 60, 95-050 Konstantynów Łódzki, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Mabion leadership page confirming Gregor Kawaletz as CEO.
- Editorial note
- Commercial biologics CDMO platform geared for recombinant protein and antibody manufacturing under GMP operating discipline.
CMO for Recombinant Proteins
GMP-compliant biologics manufacturing
Commercial biologics CDMO platform geared for recombinant protein and antibody manufacturing under GMP operating discipline.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Commercial biologics CDMO platform geared for recombinant protein and antibody manufacturing under GMP operating discipline.
Contact & location
- Website
- mabion.eu
- Company page
- Lead
- Gregor Kawaletz (verified ↗)
- Compliance
- GMP-compliant biologics manufacturing
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Commercial biologics CDMO
- Capabilities
- Recombinant Protein Manufacturing · CDMO Services · Novavax Partner Program Support
- Founded
- 2007
- Headcount
- 201-500
Clinical profileSTATUS: VERIFIED MARCH 2026
Gregor Kawaletz
Chief Executive Officer and President of the Management Board
Full addressgen. Mariana Langiewicza 60, 95-050 Konstantynów Łódzki, Poland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Mabion contact page naming the Konstantynów Łódzki headquarters and operating complex.
Open sourceCommercial biologics CDMO
Łódź, Poland. CMO for Recombinant Proteins. Review completed on 14 Mar 2026.
Polish and EU pharmaceutical oversight
GMP-compliant biologics manufacturing
CMO for Recombinant Proteins
Commercial biologics CDMO platform geared for recombinant protein and antibody manufacturing under GMP operating discipline.
Editorial note
Executing 2025-2030 ADC Expansion Strategy.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Recombinant Protein Manufacturing
CDMO Services
Novavax Partner Program Support
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Equipment detail not disclosed in the current record.
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Mabion S.A. located?
- Mabion S.A. operates from gen. Mariana Langiewicza 60, 95-050 Konstantynów Łódzki, Poland, Łódź, Poland.
- Who runs Mabion S.A.?
- Mabion S.A. is led by Gregor Kawaletz, Chief Executive Officer and President of the Management Board. Verified 14 Mar 2026.
- What certifications does Mabion S.A. hold?
- Mabion S.A. is documented under GMP-compliant biologics manufacturing.
- What does Mabion S.A. do?
- Commercial biologics CDMO platform geared for recombinant protein and antibody manufacturing under GMP operating discipline. Core capabilities: Recombinant Protein Manufacturing, CDMO Services, Novavax Partner Program Support.
Editorial context
Related technical briefs
Briefs that name Łódź as a covered market or city.